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Matthew John Andrew Wood1,*
The ability to reprogram adult somatic cells into induced pluripotent stem cells (iPSCs) and the 
subsequent development of protocols for their differentiation into disease-relevant cell types have 
enabled in-depth molecular analyses of multiple disease states as hitherto impossible. Neurons 
differentiated from patient-specific iPSCs provide a means to recapitulate molecular phenotypes of 
neurodegenerative diseases in vitro. However, it remains challenging to conduct precise manipulations 
of gene expression in iPSC-derived neurons towards modeling complex human neurological diseases. 
The application of CRISPR/Cas9 to mammalian systems is revolutionizing the utilization of genome 
editing technologies in the study of molecular contributors to the pathogenesis of numerous diseases. 
Here, we demonstrate that CRISPRa and CRISPRi can be used to exert precise modulations of 
endogenous gene expression in fate-committed iPSC-derived neurons. This highlights CRISPRa/i as 
a major technical advancement in accessible tools for evaluating the specific contributions of critical 
neurodegenerative disease-related genes to neuropathogenesis.
Parkinson’s disease (PD) is a progressive neurodegenerative disease which manifests primarily as a devastating 
movement disorder. Alpha-synuclein, encoded by the SNCA gene, is perhaps the most commonly implicated 
molecular mediator of PD pathogenesis. Point mutations1–3 and multiplications4–7 of the SNCA gene, which pro-
mote aggregation of the alpha-synuclein protein, have been described as the causes of some familial forms of 
PD. Notably, although only a small portion of all PD cases are familial in etiology, alpha-synuclein pathology is 
similarly an important mediator of sporadic forms of the disease8–10. In addition to its role as a primary mediator 
of PD, alpha-synuclein pathology has been described as a common feature of other synucleinopathies, including 
PD with dementia (PDD), dementia with Lewy bodies (DLB) and multiple systems atrophy (MSA)11,12.
Comorbidity is often observed between the synucleinopathies and other neurodegenerative diseases which 
share the common molecular events of protein misfolding or accumulation, aggregation and deposition, collec-
tively known as proteinopathies13. For example, overabundance of amyloid precursor protein, encoded by the 
APP gene, leads to its aggregation into β -amyloid, a well-established mechanism of Alzheimer’s disease (AD) 
pathology14,15. Overabundance of hyperphosphorylated microtubule-associated protein tau, encoded by the 
MAPT gene, is the central molecular pathogenic event of the tauopathies, of which AD16 and frontotemporal 
dementia with Parkinsonism linked to tau mutations on chromosome 17 (TDP-17)17 are notable examples. In 
addition, expanded CAG repeats in the HTT gene form aggregation-prone polyglutamine tracts in the huntingtin 
protein, a causative factor in Huntington’s disease (HD)18. The co-occurrence of features of synucleinopathy, amy-
loidopathy, tauopathy and polyglutaminopathy in cases that have been attributed purely to one disease classifica-
tion has spurred the concept of a continuum between these diseases13,19. Thus, the development of novel tools for 
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interrogating genetic contributions to the common processes underlying proteinopathies could result in therapies 
that benefit patients across a broad spectrum of neurodegenerative disorders13,20.
Since their discovery in 200621, induced pluripotent stem cells (iPSCs) have been well recognized for their 
potential applications in regenerative medicine and disease modeling. iPSCs are adult somatic cells which have 
been reprogrammed to a pluripotent state using defined genetic21 or chemical factors22. Human iPSCs23 can 
be derived from patients with specific diseases24, allowing investigators unprecedented opportunities to probe 
the molecular mechanisms underlying the pathogenesis of diseases in which the affected cell type is inaccessi-
ble in living patients. The first studies to reveal the utility of iPSCs in modeling diseases of the nervous system 
demonstrated that disease-specific phenotypes can be observed in iPSC-derived neurons from patients with 
familial dysautonomia25 and spinal muscular atrophy (SMA)26. iPSCs have subsequently been used in several 
studies that have yielded important insights into the molecular underpinnings of neurodegenerative diseases27–30. 
Although iPSCs have demonstrated value in elucidating disease-relevant phenotypes that have not been gleaned 
from previous models, it remains challenging to perform precise alterations of neurodegenerative disease-related 
gene expression in iPSC-derived neurons – a technique which would further enhance the utility of iPSC models 
for characterizing the specific contributions of neurodegenerative disease-related genes to neuropathogenesis. 
Recent advances in genome editing technologies have revolutionized such efforts in mammalian systems, pre-
senting novel methods for transcriptional modulation of disease-relevant gene expression in the modeling of 
complex human diseases.
The Streptococcus pyogenes CRISPR/Cas9 type II endonuclease system31 has recently been adapted for editing 
of the human genome32–34. Whereas wild-type Cas9 mediates DNA double-strand breaks, mutations of Cas9 have 
been discovered which render the endonuclease capable of cleaving only a single strand of DNA35,36 or abolish its 
endonuclease activity altogether37,38. We endeavored to explore the utility of nuclease null, or dead, Cas9 (dCas9) 
for transcriptional repression of the aforementioned proteinopathy-related genes. The D10A−/H840A− dCas9 
mutant was used to induce CRISPRi-mediated repression of SNCA, MAPT, HTT and APP via targeting to the 
transcription start sites (TSSs) of these genes. In addition to presenting data in support of the position depend-
ence of dCas9 for efficient CRISPRi, specifically proximity to the TSS, we provide evidence that the affinity of the 
dCas9:DNA interaction, as mediated by sgRNA binding, is mechanistically critical to the success of transcrip-
tional repression by CRISPRi. This data contributes to the growing body of knowledge regarding mechanistic 
determinants of CRISPRi efficacy which may eventually aid the rational design of dCas9 sgRNAs for robust 
gene silencing by CRISPRi37,39. Finally, we demonstrate that dCas9-KRAB38 and dCas9-VPR40 effector domain 
fusions can be used to exert precise alterations in the expression of the critical PD-related gene, SNCA, in human 
iPSC-derived neurons. The ability to execute precise transcriptional control over disease-associated gene expres-
sion in iPSC-derived neurons using dCas9 will further aid efforts to dissect molecular contributors to neurode-
generative diseases and provides an unprecedented opportunity to evaluate the temporal course of pathogenic 
events following neurodegenerative disease-related gene activation and repression.
Results
TSS Proximity and sgRNA-Mediated dCas9:DNA Binding Affinity are Critical Determinants of 
CRISPRi. As alpha-synuclein is well-validated as a central mediator of PD pathogenesis1–10, we first evalu-
ated the utility of dCas9 in executing transcriptional regulation of neurodegenerative disease-related genes by 
targeting the SNCA gene. SNCA is a six exon gene, wherein alternative splicing of exons 3 and 5 produces four 
transcript isoforms. As CRISPRi was previously shown to inhibit transcription elongation in E. coli and mamma-
lian cells37, we tested the possibility of inducing SNCA gene repression by designing sgRNAs to target transcribed 
regions within exons expressed in all alpha-synuclein transcript isoforms, including exons 1, 2, 4, and the exon 
1/2 splice donor (SD) and splice acceptor (SA) sites (Fig. 1a,b). However, no observable reduction in alpha-synu-
clein expression occurred using any of these sgRNAs.
We next tested whether CRISPRi could induce efficient silencing of SNCA via inhibition of transcription initia-
tion. Alpha-synuclein is expressed from at least four different promoters (Fig. 2a) based on EST sequences, cap anal-
ysis of gene expression (CAGE) from the FANTOM5 consortium41,42 and annotation in the Eukaryotic Promoter 
Database (EPDnew)43. We designed sgRNAs to the three TSSs annotated in EPDnew (human version 003). 
Specifically, sgRNAs were designed to align directly over each TSS, immediately upstream or immediately down-
stream on the non-template (NT) strand (Fig. 1a). We screened these sgRNAs for repressive activity in HEK293T 
cells and found the TSS2-1 (NT) sgRNA (henceforth TSS2-1) to have strong repressive activity when transfected 
alone, or within any combination of SNCA TSS-targeting sgRNAs (Fig. 1b). This is consistent with analysis of 
CAGE tags (Fig. 2a) and our own qRT-PCR data (Fig. 2b), which suggest that in HEK293T cells, transcription 
initiation is predominantly driven from this TSS. Analysis of CAGE tags from other tissues further indicates that 
SNCA transcription initiation in human brain tissue, neural stem cells and neurons is primarily from this TSS 
(Supplementary Table S3). Interestingly, despite sgRNA targeting to only one annotated TSS, the TSS2-1 sgRNA 
induced efficient silencing of spliced transcripts derived from all SNCA TSSs (Fig. 2c). Similar silencing of all 
TSS isoforms was observed when we analyzed nascent transcription by qRT-PCR with primers spanning specific 
exon-intron boundaries (Fig. 2d), suggesting coupling of expression from the three TSSs. The repressive effect on 
nascent transcripts further indicates that silencing by CRISPRi occurs at the level of transcription initiation, or 
the transition from initiation to elongation, rather than any post-transcriptional effect on the mRNA.
As dCas9 has been described to have superior repressive activity when targeting the non-template strand of 
a gene38, we tested whether an sgRNA aligning to the template (T) strand at the same SNCA TSS2-1 locus would 
induce silencing. Conveniently, the sequence of this guide allows a perfectly complementary sgRNA, TSS2-1 (T), 
to be designed to target an identical region on the template strand. Interestingly, the sgRNA aligning to the same 
position on the template strand was capable of inducing comparable silencing of alpha-synuclein transcript levels 
to the sgRNA on the non-template strand (Fig. 1a,b). This further suggests that the mechanism of repression may 
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not involve steric hindrance of RNA polymerase II elongation, as postulated previously38, and instead may involve 
inhibition of transcription initiation.
As the repressive effects of dCas9 were observed in the absence of an effector domain fusion, we sought to 
define mechanistic determinants of CRISPRi in the absence of a transcriptional repressor. We first evaluated 
Figure 1. Screening of sgRNAs for CRISPRi Targeting SNCA Exons and Transcription Start Sites. (a) Schematic 
representation of SNCA exon- and TSS-targeting sgRNA positions. (b) qRT-PCR screening of total alpha-synuclein 
mRNA in HEK293T cells transfected with SNCA exon- and TSS-targeting sgRNAs and dCas9. Data are represented 
as mean ± SEM. (c) HA ChIP of HEK293T cells transfected with empty dCas9 vector or TSS2-1, TSS2-2, or TSS2-3 
sgRNA co-expressing dCas9 vectors. Data are represented as mean ± SEM. (d) qRT-PCR for total alpha-synuclein 
mRNA in HEK293T, BE(2)-M17 and SH-SY5Y cells transfected with TSS2-1 sgRNA co-expressing dCas9 vector. 
Data are represented as mean ± SEM. (e) ELISA for alpha-synuclein protein in HEK293T, BE(2)-M17 and SH-SY5Y 
cells transfected with TSS2-1 sgRNA co-expressing dCas9 vector. Data are represented as mean ± SEM. * p ≤ 0.05 
compared to control, * * p ≤ 0.01 compared to control. SD = splice donor, SA = splice acceptor.
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whether sgRNA-mediated dCas9:DNA binding affinity could explain the differences in repressive activity of dif-
ferent sgRNAs targeting the same TSS. As dCas9 is expressed with an HA tag, we used an anti-HA antibody to 
Figure 2. Effect of SNCA TSS2-1 sgRNA-Mediated CRISPRi on TSS Isoform-Specific mRNA Expression 
Levels. (a) SNCA promoter region. Predicted transcripts (from UCSC Genome Browser) and transcription 
start sites (TSS) are indicated, along with the position of the TSS-targeting sgRNAs (sgRNAs). Cap analysis of 
gene expression (CAGE) data from the FANTOM5 consortium shows the relative TSS usage, averaged across 
all samples, and positions of predicted promoter regions (Promoters, p1-14@SNCA). The promoter associated 
chromatin signatures, H3K27Ac, H3K4me3 and DNaseI hypersensitivity, show data from the Encyclopedia 
of DNA Elements (ENCODE) project. Basewise conservation (PhyloP) and repeats (RepeatMasker) are also 
shown. (b) qRT-PCR analysis of TSS usage in HEK293T cells demonstrates that TSS2-1 is the predominant 
TSS. The TSS3 transcript isoform was undetectable. Data are represented as mean ± SEM. (c) Expression 
of TSS isoform-specific mRNAs following TSS2-1 sgRNA-mediated CRISPRi. Analysis of expression levels 
of total SNCA mRNA and spliced transcripts specific to TSS1, TSS2-1 and TSS2-2 by qRT-PCR in dCas9/
TSS2-1 sgRNA-transfected HEK293T cells (red bars, dCas9) relative to controls (black bars, control). Data are 
represented as mean ± SEM. (d) Analysis of nascent transcript expression following TSS2-1 sgRNA-mediated 
CRISPRi. Analysis of nascent transcripts was conducted on dCas9/TSS2-1 sgRNA transfected HEK293T cells 
(red bars, dCas9) relative to controls (black bars, control). Expression of nascent transcripts was estimated by 
qRT-PCR using primers spanning the exon 1:intron boundaries specific to transcripts deriving from TSS1, 
TSS2-1, and TSS2-2 or at the exon 2:intron and exon 3:intron boundaries. Data are represented as mean ± SEM. 
* p ≤ 0.05 compared to control, * * p ≤ 0.01 compared to control, * * * p ≤ 0.001 compared to control.
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perform chromatin immunoprecipitation (ChIP) of dCas9 from HEK293T cells transfected with an empty dCas9 
vector, lacking sgRNA expression, or a dCas9 vector co-expressing SNCA TSS2-1, TSS2-2 or TSS2-3 sgRNAs 
(Fig. 1c). TSS2-1, the sgRNA which induced the most robust gene repression, and TSS2-2, a weakly active sgRNA, 
showed enrichment at the SNCA genomic locus encompassing all three sgRNAs. In contrast, TSS2-3, an inactive 
sgRNA, was not enriched. This suggests that differences in binding affinity between different sgRNAs as well as 
their position relative to the TSS are both critical for efficient CRISPRi.
The SNCA TSS2-1 sgRNA was capable of reducing alpha-synuclein transcript (Fig. 1d) and protein (Fig. 1e) 
levels across multiple cell lines, including HEK293T, as well as the PD-relevant dopaminergic neuroblastoma 
cellular models, BE(2)-M17 and SH-SY5Y, examined by qRT-PCR and ELISA, respectively.
Multiplex Transcriptional Repression of Neurodegenerative Disease-Related Gene Expression 
using CRISPRi. We next examined whether TSS-targeting of dCas9 could be applied to silence other genes 
critically involved in neurodegenerative diseases, including the genes most commonly implicated in Huntington’s 
(HTT)18 and Alzheimer’s (MAPT and APP)14–16 diseases. Congruent with the design of sgRNAs to target SNCA 
(described above), we designed sgRNAs to target the one annotated TSSs of MAPT (Fig. 3a) and HTT (Fig. 3b), 
and the five annotated TSSs of APP (Fig. 3c) as defined in EPDnew. Silencing of all three genes was achievable 
using one or a combination of TSS-targeting sgRNAs. Finally, we examined the possibility of targeting SNCA, 
MAPT, HTT and APP in the same cells by co-transfecting the most robust sgRNAs for each gene as identified 
by screening, and were able to induce repression of all of the targeted genes in the same cells at the same time 
(Fig. 3d). This demonstrates the feasibility of using dCas9 to perform complex manipulations of gene expression 
profiles to probe the contributions of specific genes, and combinations thereof, to neurodegenerative disease 
phenotypes.
Precise Transcriptional Modulation of Alpha-Synuclein Expression in Human iPSC-Derived 
Neurons Using CRISPRa and CRISPRi. To further explore the utility of dCas9-mediated transcriptional 
alterations for interrogating the functions of neurodegenerative disease-related genes, we examined the possibility 
of using dCas9-effector domain fusions to exert precise alterations of gene expression in iPSC-derived neurons. 
NCRM-5 iPSCs were derived from a healthy control patient and express normal alpha-synuclein (NAS) levels. 
ND34391G iPSCs were derived from a patient with PD caused by alpha-synuclein triplication (AST). iPSCs were 
first quality controlled by morphological analysis, pluripotency immunostaining, karyotyping, TaqMan hPSC 
Scorecard analysis, and CNV quantification to confirm the genomic presence of two SNCA copies in NCRM-5 
iPSCs and four SNCA copies in ND34391G iPSCs (Supplementary Fig. S1). iPSCs were then differentiated into 
a stable intermediate neural stem cell (NSC) population (Supplementary Fig. S2) via dual SMAD inhibition44. 
iPSC-derived neurons were differentiated from NSCs and neuronal identity confirmed by the expression of mark-
ers of fate-committed neurons using RT-PCR (Supplementary Fig. S2) and immunostaining (Fig. 4a,b). On day 
7 of differentiation, neurons were Neon transfected in triplicate with dCas9-VPR/TSS2-2 sgRNA, dCas9-KRAB/
TSS2-1 sgRNA, or a CAG-driven tdTomato transfection control plasmid (Supplementary Fig. S2).
Using the transcriptional activator, dCas9-VPR40 and TSS2-2 sgRNA (which bound with high affinity, but did 
not induce gene silencing), we were able to induce an 8-fold activation of endogenous SNCA expression in NAS 
iPSC-derived neurons, a level approximately equivalent to the expression of alpha-synuclein in AST neurons 
(Fig. 4a). Alpha-synuclein protein levels were quantified by ELISA and were similarly found to be upregulated 
approximately 5-fold in dCas9-VPR/TSS2-2 sgRNA-transfected neurons (VPR) compared to non-transfected 
controls (NAS) (Fig. 4a). In parallel, we demonstrated that the transcriptional repressor, dCas9-KRAB38 and 
TSS2-1 sgRNA, can be used to exert a 40% reduction in alpha-synuclein mRNA levels in AST iPSC-derived 
neurons (Fig. 4b). Likewise, alpha-synuclein protein levels were reduced by approximately 60% in dCas9-KRAB/
TSS2-1 sgRNA-transfected neurons (KRAB) compared to non-transfected controls (AST) (Fig. 4b). These results 
highlight the promise of dCas9-mediated CRISPRa and CRISPRi for modeling complex neurodegenerative dis-
eases and evaluating the specific contributions of disease-associated loci by allowing precise modulation of gene 
expression in human iPSC-derived neurons.
Discussion
CRISPRa/i are gaining increasing attention as powerful tools for precise transcriptional modulation of endog-
enous gene expression. Since the discovery of this system in 201337, coupling of dCas9 to repressive domains 
has been used to enhance CRISPRi in eukaryotes38. However, our results demonstrate that even in the absence 
of repressive domains, CRISPRi represents a robust system for transcriptional silencing of eukaryotic genes in 
a position-dependent manner, specifically, when proximal to the TSS of a gene. Similar position dependence 
for efficient CRISPRi has recently been observed at other human genes, suggesting that this may be a general 
phenomenon39. We show that the effect of CRISPRi is mediated by reduction in nascent transcription. Contrary 
to our expectations, we see silencing of transcription from all TSSs when only one is targeted. This could be 
explained by coupling between promoters by mechanisms such as inhibition of common transcription factor 
binding45, shared transcription factory usage46, reduced affinity of enhancer-promoter loops47, or reduced effi-
ciency or directionality of transcription re-initiation driven by mRNA looping48. The remarkable activity of one 
sgRNA to induce transcriptional silencing from multiple TSSs of the same gene implies that robust therapeutic 
silencing of overexpressed pathogenic genes is potentially attainable with this approach.
We have also shown that sgRNA-mediated dCas9 binding affinity is a critical factor for the repressive activity 
of dCas9 in CRISPRi. This may be due to differences in the inherent binding affinity of individual sgRNAs, or 
chromatin structure around these regions. Consistent with this notion, recent data suggests that Cas9 can bind 
more effectively to sequences within DNase hypersensitive sites that are associated with promoter regions49. These 
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findings regarding the mechanism of CRISPRi will be useful in the rational design of sgRNAs for CRISPRi, and 
may eventually aid in defining new algorithms to predict activity of CRISPRi at particular genomic loci.
Figure 3. Multiplex Transcriptional Repression of Neurodegenerative Disease-Related Gene Expression 
Using CRISPRi. (a) qRT-PCR for microtubule-associated protein tau mRNA in HEK293T cells transfected with 
dCas9 sgRNAs targeting the MAPT TSS. Data are represented as mean ± SEM. (b) qRT-PCR for huntingtin 
mRNA in HEK293T cells transfected with dCas9 sgRNAs targeting the HTT TSS. Data are represented as 
mean ± SEM. (c) qRT-PCR screening of amyloid precursor protein mRNA in HEK293T cells transfected 
with dCas9 sgRNAs targeting the five annotated APP TSSs. TSSs represented in black were identified in both 
EPDnew and RefSeqGene, whereas those represented in grey are putative annotated TSSs in EPDnew. Data 
are represented as mean ± SEM. (d) qRT-PCR quantification of mRNA levels for alpha-synuclein, microtubule 
associated protein tau, amyloid precursor protein and huntingtin in HEK293T cells simultaneously transfected 
with the most active TSS-targeting dCas9 sgRNAs for SNCA, MAPT, APP and HTT. Data are represented as 
mean ± SEM. * * p ≤ 0.01 compared to control, * * * p ≤ 0.001 compared to control.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:28420 | DOI: 10.1038/srep28420
Figure 4. CRISPRa- and CRISPRi-Mediated Modulation of Alpha-Synuclein Transcript and Protein 
Expression Levels in Human iPSC-Derived Neurons. (a) CRISPRa-mediated activation of alpha-synuclein 
in NAS iPSC-derived neurons with TSS2-2 sgRNA and dCas9-VPR transcriptional activator. mRNA levels 
were quantified by qRT-PCR in biological triplicate, and data are represented as mean ± SEM. Protein levels 
were quantified by ELISA in biological triplicate, and data are represented as mean ± SEM. (b) CRISPRi-
mediated repression of alpha-synuclein in AST iPSC-derived neurons with TSS2-1 sgRNA and dCas9-KRAB 
transcriptional repressor. mRNA levels were quantified by qRT-PCR in biological triplicate, and data are 
represented as mean ± SEM. Protein levels were quantified by ELISA in biological triplicate, and data are 
represented as mean ± SEM. Micrographs demonstrate the neuronal identity of iPSC derivatives as confirmed 
by co-immunostaining with the pan-neuronal markers, MAP2 and TUJ1 (scalebars are 100 μ m). Schematic 
diagrams represent the intended outcome of CRISPRa/i-mediated gene expression modulation. * p ≤ 0.05 
compared to control, * * p ≤ 0.01 compared to control, * * * p ≤ 0.001 compared to control. NAS = normal alpha 
synuclein; AST = alpha-synuclein triplication.
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We employed TSS-targeting via CRISPRi to induce multiplex silencing of genes involved in proteinopathy-induced 
neurodegeneration, further confirming that the targeting of CRISPRi to the TSS can be broadly applied and sup-
porting the notion that simultaneous targeting of multiple genes involved in common pathological processes can 
be accomplished with CRISPRi. Importantly, we have demonstrated that both CRISPRa and CRISPRi can be used 
to execute precise transcriptional modulation of neurodegenerative disease-related genes in human iPSC-derived 
neurons. Such a technique will allow investigations of the temporal series of events resulting from manipulation 
of disease-related gene expression levels. This will enable evaluation of the order of molecular changes that result 
in particular phenotypic outcomes, both during disease progression and upon therapeutic intervention. In addi-
tion to the applicability of this approach for studying genes which are commonly implicated in the pathogenesis 
of neurodegenerative diseases, such an approach could potentially be used to examine the influence of particular 
pathways in these diseases, by perturbation of one or multiple pathway components50.
CRISPRa/i provide a valuable approach to conducting experimental alterations of gene expression. Both have 
similar efficacy to other methods for gene activation and repression, while possessing the comparable advan-
tages of ease of design, cost effectiveness and manipulations of genes from their endogenous genomic contexts. 
CRISPRa/i would be predicted to elicit reduced off-target effects since Cas9 can tolerate fewer mismatches 
within the sgRNA sequence51–53 and additionally requires the presence of a protospacer adjacent motif (PAM)38. 
Although it appears that binding of dCas9 is more promiscuous than cleavage activity49,54 and requires a shorter 
region of complementarity with the sgRNA55, the specificity of repression elicited by dCas9 can be very high56. 
Our data and that of others39 suggest that only those sgRNAs targeting in close proximity to a TSS will elicit 
changes in gene expression, which reduces the chances of off target effects considerably. With growing knowledge 
of the mechanism by which CRISPRa/i can be induced efficiently and specifically, these tools can be expanded 
to dissect the specific influence of genes with putative roles in other neurodegenerative diseases such as C9orf72 
in ALS/frontotemporal dementia (FTD) and LRRK2 in PD as well as in the development of therapies for such 
diseases. The application of CRISPRa/i to iPSC models will further extend the utility of both systems for modeling 
complex diseases and may aid in the development of novel CRISPR/Cas9-based therapeutic approaches.
Methods
HEK293T, SH-SY5Y and BE(2)-M17 Cell Culture and Transfection. HEK293T and SH-SY5Y 
cells were maintained in DMEM (Life Technologies) supplemented with 10% HyClone FBS (GE Healthcare). 
BE(2)-M17 cells were maintained in OptiMEM (Life Technologies) supplemented with 10% HyClone FBS. 
Medium was changed every two days and cells were passaged when 70% confluent. HEK293T and BE(2)-M17 
cells were seeded at a density of 1.3 × 105 cells per well to 24-well plates 24 hours before transfection with 
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s protocol. Cells were transfected in trip-
licate with 500 ng final DNA used per well. SH-SY5Y cells were Neon (Life Technologies) transfected at a density 
of 1 × 106 cells per reaction according to the manufacturer’s protocol, using default system settings (1400 V, 20 ms, 
1 pulse). Cells were transfected in triplicate with 2 μ g final DNA used per reaction. A CAG-driven tdTomato 
expression vector was used as a transfection control for all experiments.
Differentiation and Transfection of iPSC-Derived Neurons. NCRM-5 iPSCs, derived from a healthy 
control subject with normal alpha-synuclein (NAS) expression levels, were obtained from the NIH Center for 
Regenerative Medicine (NIH CRM) and are distributed through RUDCR Infinite Biologics at Rutgers University. 
ND34391G iPSCs, derived from a patient with PD caused by alpha-synuclein triplication (AST), were obtained 
from the Coriell Institute and are distributed through the NINDS Repository Fibroblasts and iPSCs Collection. 
NCRM-5 and ND34391G iPSCs were quality controlled by comparison to the following established iPSC lines: 
NCRM-1 iPSCs, derived from a healthy control subject, obtained from the NIH CRM and distributed through 
RUDCR Infinite Biologics at Rutgers University; NHDF-1 iPSCs, derived from a healthy control subject and 
obtained from the James Martin Stem Cell Facility; ND38477C iPSCs, derived from a patient with PD caused by a 
compound heterozygous 255A and exon 3–4 deletion in the PARK2 gene, obtained from the Coriell Institute and 
distributed through the NINDS Repository Fibroblasts and iPSCs Collection (Supplementary Fig. S1). Normal 
alpha-synuclein (NAS) and alpha-synuclein triplication (AST) neurons were differentiated from NCRM-5 and 
ND34391G iPSCs, respectively, via a stable intermediate iPSC-derived NSC population (Supplementary Fig. S2). 
On day 0, 7.5 × 106 NSCs were seeded onto poly-L-ornithine (Sigma)/laminin (Life Technologies)-coated T75 
tissue culture flasks. On day 1, 100% medium was replaced with Neuronal Differentiation Medium consisting 
of Neurobasal (Life Technologies), 1X B27 supplement (Life Technologies), 1X GlutaMAX (Life Technologies), 
20 ng/mL BDNF (R&D Systems) and 20 ng/mL GDNF (R&D Systems). 100% medium was replaced every other 
day. On day 7, neuronal progenitors were dissociated with Accutase (Life Technologies). Neuronal progeni-
tors were Neon transfected at a density of 5 × 105 cells per reaction with dCas9 and sgRNA expression plas-
mids according the manufacturer’s protocol, using default system settings (1400 V, 20 ms, 1 pulse). Neuronal 
progenitors were transfected in triplicate with 2 μ g final DNA used per reaction. A CAG-driven tdTomato 
expression vector was used as a transfection control for all experiments (Supplementary Fig. S2). Following 
Neon transfection, cells were plated directly onto poly-ornithine/laminin-coated 12-well tissue culture dishes 
in Neuronal Differentiation Medium containing 10 μ M ROCK inhibitor (Tocris Bioscience) to promote survival 
and 0.5 mM dbcAMP (Sigma) to promote maturation. Neurons were processed for analysis 72 hours after trans-
fection. Neuronal identity was characterized by immunostaining for the pan-neuronal markers MAP2 and TUJ1 
(Fig. 4a,b), as described below, and RT-PCR for markers of fate-committed neurons, including MAP2, TUJ1, 
NGN2, doublecortin, and neurofilament (Supplementary Fig. S2), as described below. All RT-PCR primers are 
listed in Supplementary Table S2.
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CRISPRi and CRISPRa Vector Design and Construction. CRISPRi constructs were generated from the 
pAC154-dual-dCas9VP160-sgExpression vector, which was a gift from Rudolf Jaenisch (Addgene #48240)57, by 
replacement of the VP160 domain with a puromycin acetyl transferase gene, with or without substitution of the 
sgRNA backbone, as described below. sgRNAs for inhibition of transcript elongation were designed to align at 
SNCA exon 1, 2, 4, and the exon 1/2 slice donor (SD) and splice acceptor (SA), and were expressed from a dCas9 
vector with an unmodified sgRNA backbone. Constructs for TSS targeting of SNCA, HTT, MAPT and APP were 
designed to overlap the TSS, or to align immediately upstream or downstream of the TSS without overlapping. 
For CRISPRi, TSS-targeting sgRNAs were co-expressed in a dCas9 vector containing a modified F + E sgRNA 
backbone, where F + E refers to two modifications of the sgRNA backbone: F, an A – U basepair flip which abol-
ishes a putative RNA polymerase III terminator (4 consecutive U’s) in the sgRNA stem-loop, and E, an extended 
dCas9-binding hairpin structure58. sgRNA oligos were annealed and subsequently ligated into dCas9 or dCas9 
F + E vectors digested with Bbs I (NEB). For CRISPRa, SNCA TSS2-2 sgRNA and modified F + E sgRNA back-
bone were cloned with a human U6 promoter by overlap PCR into pGEM-Teasy (Promega) and co-transfected 
with the SP-dCas9-VPR vector, which was a gift from George Church (Addgene #63798)40. All sgRNA oligonu-
cleotides are listed in Supplementary Table S1.
RNA Extraction, Reverse Transcription, RT-PCR and qRT-PCR. Total RNA was extracted using 
the miRNeasy Mini Kit (Qiagen). cDNA was reverse transcribed from 1 μ g of HEK293T and BE(2)-M17, 
500 ng of SH-SY5Y, 350 ng of NAS iPSC-derived neuron, and 250 ng of AST iPSC-derived neuron RNA, using 
SuperScriptIII First-Strand Synthesis SuperMix for qRT-PCR (Life Technologies), per the manufacturer’s instruc-
tions. RT-PCR was performed using undiluted cDNA and Platinum PCR SuperMix (Life Technologies), per the 
manufacturer’s instructions. For qRT-PCR, HEK293T and BE(2)-M17 cDNA was diluted 1:200, SH-SY5Y cDNA 
was diluted 1:100, NAS iPSC-derived neuron cDNA was diluted 1:70, and AST iPSC-derived neuron cDNA was 
diluted 1:50 in nuclease-free water (Ambion). For nascent transcript analysis, RNA was DNase treated prior to 
qRT-PCR using the TURBO DNA-free Kit (Ambion), per the manufacturer’s instructions. qRT-PCRs were run 
with standard cycling using KiCqStart SYBR Green Master Mix (Sigma). All RT-PCR and qRT-PCR primers are 
listed in Supplementary Table S2.
Quantification of Alpha-Synuclein Protein by ELISA. HEK293T, BE(2)-M17 and SH-SY5Y cells, as 
well as iPSC-derived neurons were collected in Cell Extraction Buffer (Life Technologies), supplemented with 
PMSF (Sigma) and protease and phosphatase inhibitors (Thermo Scientific) 72 hours after transfection. ELISA 
was performed using the Human Alpha-Synuclein ELISA Kit (KHB0061, Life Technologies), following the man-
ufacturer’s instructions. Briefly, samples and Alpha-Synuclein Standards were prepared in Sample Diluent Buffer 
and added to Alpha-Synuclein Antibody-coated assay wells in duplicate. Alpha-Synuclein Detection Antibody 
was added to assay wells and plates were incubated at room temperature for three hours. Assay wells were washed 
four times with 1X Wash Buffer and Anti-Rabbit IgG HRP was added to each well. Plates were incubated for 
30 min at room temperature. Assay wells were washed 4 times with 1X Wash Buffer and Stabilized Chromogen 
was added. Wells were incubated for 30 min at room temperature, after which an equal volume of Stop Solution 
was added and absorbance was read at 450 nm. A standard curve was created in GraphPad Prism 6 (GraphPad 
Software) and the program was used to calculate the unknown concentrations of alpha-synuclein in cell lysates.
HA ChIP. HEK293T cells were seeded at a density of 1 × 106 cells to 6-well tissue culture dishes. Cells were 
transfected in triplicate with Lipofectamine 2000 using 2500 ng DNA per well. After 48 hours, cells were harvested 
by rinsing once with cold PBS, applying TrypLE (Life Technologies) until cells detached, and breaking into single 
cells by trituration with equal volume DMEM supplemented with 10% HyClone FBS. Cells were counted and 
2.2 × 106 cells were processed for sonication. Cells were pelleted by centrifugation at 1300 rpm for 5 min. Cells 
were washed once with 500 μ L of cold PBS. Supernatant was discarded and cells were resuspended in 500 μ L 
of fresh cold PBS. Cross-linking was initiated by the addition of 13.5 μ L of 35.6 – 38% formaldehyde (Sigma) 
for 10 min at room temperature. Subsequently, 57 μ L of 1.25 M glycine was added for 5 min at room tempera-
ture to quench the reaction. A volume of 143 μ L complete Buffer B (Diagenode) containing protease inhibitor 
(Diagenode) was added and samples were incubated for 5 min on ice. Chromatin was sheared using a Bioruptor 
(Diagenode) with high setting for 3 rounds of 10 cycles, each 30 sec on, 30 sec off, after which 957 μ L complete 
Buffer A (Diagenode) containing protease inhibitors (Diagenode) was added to dilute SDS. An aliquot of chroma-
tin from 200,000 cells (100 μ L) was analyzed for shearing efficiency by phenol:chloroform extraction and ethanol 
precipitation and products visualized on a 1.5% agarose gel. Insoluble material was removed by centrifugation 
at 16,000 × g for 15 min at room temperature, and soluble chromatin pre-cleared with 40 μ L protein A agarose 
(Millipore) for 1 hour. A sample of 40 μ L was taken as 10% input, 400 μ L for mock ChIP using protein A beads 
alone and 400 μ L for HA-Cas9 ChIP with a rat monoclonal anti-HA antibody (3F10 affinity matrix 11815016001, 
Roche). Samples were incubated overnight at 4 °C with rotation, and washed once in low salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 8.0), once in high salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl pH 8.0), once in lithium chloride wash 
buffer (0.25 M LiCl, 1% NP-40, 1% Na-Deoxycholate, 1 mM EDTA-NaOH pH 8.0, 10 mM Tris-HCl pH 8.0) and 
twice in TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA). Chromatin was eluted from the beads with 100 μ L elu-
tion buffer (1% SDS, 0.1 M NaHCO3) for 5 min at 65 °C and 30 min at 25 °C, and crosslinking reversed overnight 
at 65 °C alongside the input samples. DNA was purified after digestion with 100 μ g/ml RNase A for 1.5 hours at 
42 °C and 200 μ g/ml proteinase K for 1 hour at 45 °C using ChIP DNA Clean and Concentrator Columns (Zymo). 
DNA was analyzed by qPCR and results are represented as % input. Primer sequences are listed in Supplementary 
Table S2.
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Immunostaining. For immunostaining, cells were fixed with 4% paraformaldehyde diluted in 1X PBS for 
15 min. Fixative was removed and cells rinsed three times with 1X PBS for 5 min each wash. Cells were then 
blocked with a solution of 0.3% Triton X-100 and 5% goat serum in 1X PBS for one hour at room temperature. 
Blocking reagent was aspirated and primary antibodies were applied in antibody dilution buffer (0.3% Triton 
X-100, 1% BSA in 1X PBS) for overnight incubation at 4 °C. Primary antibodies were aspirated, and cells were 
rinsed three times with 1X PBS for 5 min each wash. Secondary antibodies were applied for two hours at room 
temperature. Secondary antibodies were then removed and samples rinsed three times with 1X PBS for 5 min 
each. The cells were then mounted with Vectashield Mounting Medium with DAPI (Vector Labs) and glass cover-
slips. Images were acquired using an EVOS FL Imaging System (Life Technologies). The following antibodies were 
used for immunostaining of neurons: MAP2 (Cell Signaling, 4542), TUJ1 (Cell Signaling, 4466), goat anti-rabbit 
Alexa Fluor 488 (Life Technologies, A-11034), and goat anti-mouse Alexa Fluor 555 (Life Technologies, A-21424).
Statistical Analysis. All qRT-PCR data represent the results of three biological replicates, analyzed in 
technical triplicates. TaqMan hPSC Scorecard analysis was performed with one biological replicate per cell line. 
Biological triplicates were analyzed by alpha-synuclein ELISA. Statistical analysis was performed using SPSS 
Statistics 22 (IBM). Levene’s homogeneity test was used to evaluate the null hypothesis that population variances 
were equal. Significance was determined by one-way analysis of variance (ANOVA) with post-hoc Bonferroni 
where samples met the homogeneity of variances assumption or Games-Howell where samples did not meet the 
homogeneity of variances assumption.
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